Trial Profile
A randomized phase III study of continuous maintenance Bevacizumab with or without Pemetrexed after induction therapy of Carboplatin, Pemetrexed, and Bevacizumab in patients with advanced non-squamous non-small-cell lung cancer whose EGFR mutation status is not active (other than Exon 19 deletion or Exon 21 point mutation) or is not known
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Oct 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Pemetrexed (Primary) ; Carboplatin
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms COMPASS
- 27 Dec 2019 Results published in the Journal of Clinical Oncology
- 04 Jun 2019 Primary endpoint (Overall survival from the date of randomization for maintenance therapy) has not been met as per results presented at the 55th Annual Meeting of the American Society of Clinical Oncology
- 04 Jun 2019 Results presented at the 55th Annual Meeting of the American Society of Clinical Oncology